Trial Profile
A Phase II, Open-Labeled, Multi-Center, Randomized Controlled Trial of Vinblastine +/- Bevacizumab for the Treatment of Chemotherapy-Naïve Children With Unresectable or Progressive Low Grade Glioma (LGG)
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 05 Feb 2024
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Vinblastine
- Indications Glioma; Neurofibromatosis 1
- Focus Therapeutic Use
- 29 Jan 2024 Planned primary completion date changed from 1 Aug 2026 to 31 Jul 2024.
- 29 Jan 2024 Status changed from recruiting to active, no longer recruiting.
- 23 Dec 2016 Status changed from not yet recruiting to recruiting.